drugset / Trial / NCT02404103

Flunisolide HFA in Children With Small Airway Disease

NCT02404103

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.

Timeline

Start
2015-03
Primary completion
2017-05
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flunisolide Small molecule 80 ug Inhaled
Comparator Flunisolide Small molecule 160 ug Inhaled